Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.48 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6566160 | 0.91 | EGLN1 (0.47) | EGLN1FTOKDM5BKDM2AEGLN3 | |
| SCHEMBL8628487 | 0.90 | EGLN1 (0.50) | EGLN1FTOGCGRSHMT2 | |
| SCHEMBL6564074 | 0.89 | EGLN1 (0.45) | EGLN1FTOKDM5BKDM2AEGLN3 | |
| SCHEMBL6565232 | 0.88 | EGLN1 (0.44) | EGLN1FTOKDM5BKDM2AEGLN3 | |
| SCHEMBL8779216 | 0.86 | EGLN1 (0.49) | EGLN1FTOEGLN3 | |
| Hydrochloric Acid SCHEMBL6565656 | 0.85 | EGLN1 (0.48) | EGLN1FTOEGLN3 | |
| SCHEMBL6567188 | 0.84 | EGLN1 (0.47) | EGLN1FTOEGLN3 | |
| SCHEMBL6565865 | 0.84 | EGLN1 (0.57) | EGLN1FTOEGLN3 | |
| SCHEMBL6567446 | 0.83 | EGLN1 (0.46) | EGLN1FTOEGLN3 | |
| SCHEMBL8632215 | 0.83 | EGLN1 (0.46) | EGLN1FTOEGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2015-03-19 | — | — | US | claimed |
| CN-101664551-B | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN INC | 2013-08-14 | — | — | CN | claimed |
| CN-101664408-B | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN INC | 2013-05-01 | — | — | CN | claimed |
| EP-1463823-B1 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN INC (US) | 2013-03-06 | — | — | EP | claimed |
| CN-102552261-A | Methods of increasing endogenous erythropoietin EPO | FIBROGEN INC | 2012-07-11 | — | — | CN | claimed |
| CN-101664409-A | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN INC | 2010-03-10 | — | — | CN | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| US-5719164-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-17 | — | — | US | claimed |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| EP-2298301-B2 | MEDICAMENTS FOR TREATING ANEMIA ASSOCIATED WITH KIDNEY DISEASE | FIBROGEN INC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003053997-A2 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003049686-A2 | STABILIZATION OF HYPOXIA INDUCIBLE FACTOR (HIF) ALPHA | FIBROGEN, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| US-5726305-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-03-10 | — | — | US | disclosed |
| US-5719164-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-17 | — | — | US | disclosed |
| EP-0765871-A1 | Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885FTO 1391/4885KDM5B 535/4885 |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | EGLN1 863/4885FTO 4661/4885KDM5B 2288/4885 |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | EGLN1 24/4885FTO 1546/4885KDM5B 1712/4885 |
| US-11680047-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | EGLN1 21/4885FTO 1235/4885KDM5B 1880/4885 |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885FTO 1391/4885KDM5B 535/4885 |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | EGLN1 24/4885FTO 1546/4885KDM5B 1712/4885 |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | EGLN1 13/4885FTO 2629/4885KDM5B 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.